Braveheart Bio Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

Div yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

URL

https://www.braveheart.bio

IPO date

Employees

Domiciled in

Incorporated in

Valuation

No data to show